Pacira BioSciences (PCRX): Customer Relationships That Drive Revenue and Risk

Pacira sells non-opioid pain-management products and device therapies, monetizing primarily through commercial sales of EXPAREL, ZILRETTA and iovera to healthcare providers and through distribution agreements with large pharmaceutical wholesalers and select regional partners. Revenue flows from direct product sales, drop-shipped orders through wholesalers, and licensing/partner economics (upfront payments, transfer pricing and tiered royalties) for international rights. For investors, the core thesis is simple: Pacira’s top-line growth and cash flow are highly dependent on EXPAREL commercialization, concentrated wholesale distribution, and expanding partner deals to reach non‑U.S. markets.
Explore more on partner and counterparty risk at https://nullexposure.com/.

How Pacira actually operates and gets paid

Pacira markets three commercial products and sells predominantly into the hospital and anesthesia channel. EXPAREL accounted for 78% of 2024 revenue, making it the linchpin of the business; ZILRETTA and iovera contribute the remainder and represent diversification in near-term product mix. The company uses a mix of direct sales to providers and wholesale distribution: it drop-ships EXPAREL directly to end-users on orders routed through wholesalers, so Pacira retains control of product custody even when wholesalers handle commercial ordering and billing. According to public filings, Pacira also leverages licensing relationships to expand geographic reach, receiving upfront payments and ongoing transfer prices and royalties for partner commercializations.

Operating-model constraints that matter for investors

Concentration of revenue and receivables: Company-level disclosures identify heavy concentration with a small number of large wholesalers and a single product driving most sales; this elevates counterparty and product risk for collections and price leverage.
Geographic footprint is concentrated in North America with selective EMEA exposure: Revenue mix and product approvals skew toward the U.S., with EXPAREL also sold in the E.U. and U.K.; recent partner deals target Asia‑Pacific.
Seller posture and logistics control: Pacira’s drop-ship model means it still controls fulfillment, which preserves product quality and compliance but leaves commercial payment exposure to large wholesalers.
Maturity and criticality: EXPAREL’s dominance signals high criticality of one core product for near-term results; ZILRETTA provides material but secondary support. These are company-level signals drawn directly from Pacira’s public disclosures.

If you want a structured view of counterparties and how they affect cash flow, see https://nullexposure.com/ for more analysis.

Relationship roll-call: who Pacira names and what they mean for investors

McKesson Drug Company — McKesson accounted for 34% of Pacira’s total revenue in FY2024, making it the single largest wholesale channel for product distribution and cash receipts. According to Pacira’s FY2024 10‑K, this relationship represents the largest concentration among wholesalers.
Source: Pacira 2024 Form 10‑K (disclosure of three wholesalers and revenue percentages, FY2024).
Cardinal Health, Inc. — Cardinal Health represented 23% of total revenue in FY2024, placing it as the second major wholesale counterparty and a meaningful contributor to Pacira’s working capital profile. This concentration elevates counterparty payment risk and negotiation leverage.
Source: Pacira 2024 Form 10‑K (FY2024 revenue concentration disclosure).
AmerisourceBergen Health Corporation — AmerisourceBergen accounted for 20% of Pacira’s FY2024 revenue, completing the trio of wholesalers responsible for a substantial share of net product sales and accounts receivable. The company warns that non‑payment by these wholesalers could materially impact liquidity.
Source: Pacira 2024 Form 10‑K (FY2024 wholesalers disclosure).
Aetna (CVS) — Pacira management referenced a policy shift among major payers including Aetna during its Q4 2025 earnings call, signaling payer-level changes that influence reimbursement and adoption for pain-management therapies. This is a payer-side dynamic that affects demand and utilization economics with providers.
Source: Pacira Q4 2025 earnings call (discussion of payer policy shifts, 2025Q4).
Cigna (CI) — Cigna was cited alongside Aetna and Humana in the Q4 2025 call as part of a broader payer-policy movement; such payer actions affect coverage, prior authorization and ultimately unit demand for Pacira’s products.
Source: Pacira Q4 2025 earnings call (2025Q4).
Humana (HUM) — Humana was named by management when describing payer trends; changes in Humana’s reimbursement posture are relevant for outpatient and surgical settings where Pacira’s products are used.
Source: Pacira Q4 2025 earnings call (2025Q4).
TRICARE — TRICARE was explicitly included in management’s commentary on large payer policy shifts during the Q4 2025 call, indicating that even government-backed payer programs are part of the evolving reimbursement landscape Pacira addresses.
Source: Pacira Q4 2025 earnings call (2025Q4).
J&J MedTech (Johnson & Johnson) — Management listed J&J MedTech as a strategic partner expected to gain traction, positioning Pacira to leverage large medical-device distribution and channel expertise in adjacent markets. This partnership signals strategic co‑commercialization rather than simple distribution.
Source: Pacira Q4 2025 earnings call (management commentary, 2025Q4).
LG Chem — Pacira signed an agreement granting LG Chem exclusive rights to commercialize EXPAREL in select Asia‑Pacific territories; Pacira received an upfront payment, will supply product at a transfer price, and will earn tiered royalties on future sales. This deal shifts international commercial risk to a regional partner while preserving a stream of partner-derived revenue.
Source: Company press releases and news coverage (GlobeNewswire and BioSpectrumAsia, January–February 2026; reporting FY2026).

Investment implications: concentration, partner strategy, and downside vectors

Concentration is the dominant theme: EXPAREL’s 78% share of sales and the top-three wholesalers capturing the bulk of revenue create high single-product and counterparty concentration risk that directly affects cash flow volatility and negotiating leverage.
Partnering reduces territory execution risk but trades growth for royalty economics: The LG Chem agreement demonstrates a repeatable model—upfront payments, transfer-price supply and royalties—that expands geographic reach while reducing Pacira’s operational footprint in APAC.
Payer dynamics are an active variable: Management’s explicit call-out of payer policy shifts (Aetna, Cigna, Humana, TRICARE) makes reimbursement a live driver of near-term utilization and pricing pressure.
Operational control via drop-ship mitigates some product-quality and compliance risks but leaves collections concentrated with wholesalers.

For a deeper counterparty and receivables risk profile tailored to investment due diligence, visit https://nullexposure.com/.

What to watch next

Quarterly updates on revenue mix and whether EXPAREL’s percentage of total revenue declines meaningfully as ZILRETTA and iovera scale.
Receivables days and concentration trends among the three largest wholesalers.
Early commercial traction reports from LG Chem in selected APAC markets and any expansion of licensing economics.
Public payer policy announcements from Aetna, Cigna, Humana and TRICARE that could change utilization patterns.

Final takeaway: Pacira’s growth is powered by a dominant product and a small set of large distribution and payer relationships; this structure offers strong upside if EXPAREL adoption and partner royalties scale, but it also concentrates financial and execution risk—exactly the mix investors should monitor in the coming quarters. Visit https://nullexposure.com/ for ongoing counterparty intelligence and relationship risk scoring.